Year None20212020201920182017 Jul 09, 2021 F-star Therapeutics to Present at Upcoming Investor Conferences PDF Version Jul 08, 2021 F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors PDF Version May 17, 2021 F-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update PDF Version May 10, 2021 F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021 PDF Version May 07, 2021 F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock PDF Version May 06, 2021 F-star Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PDF Version Apr 29, 2021 Cancer Trial Highlights Potential for Checkpoint Inhibitors Apr 19, 2021 Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy PDF Version Apr 10, 2021 F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster PDF Version Apr 01, 2021 F-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology Collaboration PDF Version Pagination Current page 1 Page 2 Next page Next
